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Abstract
Background: Stereotactic body radiation therapy (SBRT) using intensity-modulated radiotherapy (IMRT) with dose
escalation by simultaneous integrated boost (SIB) can be a safe modality for treating spinal bone metastases with
enhanced targeting accuracy and improve local tumor control.
Methods/Design: This is a single-center, prospective, randomized, controlled trial. One hundred and twenty
patients with spinal bone metastases will receive palliative radiation therapy at the Heidelberg University Hospital.
SBRT will be given in five or ten fractions with or without SIB. Four treatment arms are planned: IMRT with 30 Gy in
ten fractions, IMRT with 30 Gy in ten fractions and SIB to 40 Gy, IMRT with 20 Gy in five fractions, and IMRT with
20 Gy in five fractions and SIB to 30Gy in five fractions will be compared. The target parameters will be measured at
baseline level and at three and six months after radiation.
Discussion: The primary endpoint of this study was to assess and compare the local tumor control (by means of
different fractionation schedules and biological doses to the tumor area). Secondary endpoints are acute and
chronic adverse events, pain relief, quality of life, and fatigue.
Trial registration: ClinicalTrials.gov, NCT02832765. Registered on 27 July 2016.
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Background
Two-thirds of all cancer patients develop bone metasta-
ses during the course of their disease [1]. This form of
distant relapse occurs from many types of solid cancers,
especially from lung, breast, and prostate [2]. Bone
involvement can also be extensive in certain hematologic
malignancies [3, 4]. About 30% of all skeletal metastases
and 10% of all primary bone tumors are located in the
spinal column [5], mostly the lumbar (52%), thoracic
(36%), and cervical (12%) spine [6]. The exact mechanism
of bone metastasis is not fully understood. It is postulated
that bone metastases arise as a detachment of tumor cells
from the primary tumor and reach the bone by intravascu-
lar penetration, resulting in adhesion in distinct bone
areas. The tumor cells cause local changes of the bone
structure, caused by an imbalance of bone remodeling.
Bone metastases present as osteoplastic, osteolytic, or
mixed osteolytic/osteoplastic tumor masses. Many meta-
static bone lesions cause few or no symptoms, but for
skeletal-related events, pain is the most common symp-
tom; many patients with bone metastasis experience
significant pain at some point during their disease course
[7]. Other skeletal-related events include reduce activity in
daily life (ADL), decreased energy, hypercalcemia, and risk
of pathological fractures and neurological deficits. Patho-
logic bone fractures occur in 5% and spinal cord
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compression in 10–15% [5]. Restrictions of movement of
the spinal column may have a devastating long-term
impact on function, mobility, independence, health, and
quality of life (QoL). External beam radiotherapy has an
established role in the management of patients with bone
metastases of the spine. The fractionation schedule apply-
ing 30 Gray in ten fractions is a safe and effective treat-
ment modality commonly used to achieve palliation of
pain associated with spinal metastases [8]. In about 50–
80% of the patients, a decrease of pain is reported and
about 30% of the patients showed complete remission of
pain [8]. Stereotactic body radiation therapy (SBRT) using
intensity-modulated radiotherapy (IMRT) can be a safe
treatment option for treating spinal metastasis with
enhanced targeting accuracy [9, 10]. Published data report
that IMRT to the spine was well tolerated, had no signifi-
cant late toxicities, and spared other organs at risk [11].
Pre-treatment megavoltage computed tomography (CT)
allows for the control of the patient position and improves
treatment accuracy [12].
This study aims at evaluating therapeutic outcomes in
terms of local control through a higher biological dose
in the tumor area by using SIB-IMRT and to test shortened
fractionation schedules in palliative patients. Toxicity, fa-
tigue, and QoL improvements will be evaluated. To the best
of our knowledge, no comparable randomized study has
been described in the literature so far.
Methods/Design
This is a prospective, randomized, single-center, con-
trolled, exploratory intervention study with four parallel
treatment groups aimed at comparing local control rates
after RT with and without SIB in patients with bone
metastases of the spine. Four different schedules will be
evaluated: IMRT with 30 Gy in ten fractions to the
whole vertebral body, IMRT with 30 Gy in ten fractions
to the whole vertebral body with the application of a SIB
to 40 Gy, 20 Gy in five fractions to the whole vertebral
body or IMRT with 20 Gy in five fractions to the whole
vertebral body with the application of a SIB to 30 Gy.
Before enrolment in the study, patients will receive CT
and if necessary magnetic resonance imaging (MRI)-
based staging examinations to measure the spinal cord
dimension. If intraspinal metastases are suspected, an
MRI examination is performed beforehand.
RT is performed in systemic/targeted therapy free
interval. Radiation therapy will be applied in five frac-
tions per week (Monday to Friday).
After recording the baseline measurements, patients will
be randomly assigned to one of the four groups. Target
parameters will be measured and recorded at baseline (t1),
at week 12 (t2), and again at week 24 (t3) (Fig. 1). Follow-
up measurements are scheduled to take place at 12, 18,
and 24 months after the completion of RT (Fig. 2).
Recruitment and randomization
The patients will be given all the relevant information
about the study by the radiation oncologist at their first
presentation to our department (approximately 1–2 weeks
before the start of RT). If patients are interested in partici-
pating in the study, they will receive a second appoint-
ment in order to further inform them and to obtain
informed consent. A block randomization procedure will
be used to ensure even distribution of patients into the
four groups. The randomization procedure will be carried
out by a central office. The study personnel responsible
for the recruitment and patient care will have no access to
the randomization information and the study director will
have no influence on the recruitment of patients. The re-
cruitment phase will be concluded with the attainment of
the planned number of patients (120 patients in total, 30
patients in each group). Projected recruitment time will
be 12 months, and recruitment is scheduled to start in
February 2017. Regular study follow-up will end two years
Fig. 1 Flow chart of IRON-2 trial; t0 = randomization, t1 = end of RT, t2 (3 months after RT) = restaging, t3 (6 months after RT) = restaging
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after enrolment or, where applicable, with the respective
patient’s death.
Inclusion criteria
 Patients with histologic confirmation of a tumor
disease, demonstrating metachronic solitary or
multiple metastatic bone lesions of the thoracic or
lumbar spine or the sacral bone
 Indication for RT of the bone metastases
 MRI-based staging examinations (if necessary)
 Age 18–85 years
 Karnofsky Index ≥ 50% [13]
 Signed declaration of informed consent
Exclusion criteria
 Significant neurological or psychiatric disorders,
including dementia and epileptic seizures
 Patients with myeloma, lymphoma, or sarcoma
 Previous RT to the treatment area
 MSCC
 Other severe disorders that may prevent the
patient’s participation in the study
 Diminished legal capacity
 Any medical of psychological condition that the
study director considers a preventive factor for the
patient’s ability to complete the study or to
adequately understand the scope of the study and to
give his/her consent
Assessment of the primary and secondary endpoints
The aim of the study is to evaluate local control rates in
metastatic bone disease. The primary endpoint is defined
by bone remodeling according to density in the metasta-
sis. Bone density will be measured at the irradiated re-
gion at baseline and at the three-month time-point after
the completion of RT (t2). Furthermore, the local control
is assessed by CT imaging taken before and at three and
six months after radiation treatment. Secondary end-
points are vertebral stability, QoL, fatigue, pain, overall
survival, bone survival, pathological fracture, and neuro-
logical deficits. The baseline examination will be carried
out immediately before the start of therapy and is sched-
uled to comprise the comprehensive recording of the
socio-demographic data, the recording of the current
pain situation (VAS score), the extent of fractures, the
QoL, and the current degree of fatigue. The follow-up
examinations will take place after the end of RT, as
mentioned above (Fig. 1).
The secondary endpoints such as overall survival,
fatigue, QoL, and anxiety will be recorded by using vali-
dated questionnaires (EORTC QLQ FA13 [14], EORTC
QLQ BM22 [15], and the questionnaire to record stress
in patients with cancer [FBK] according to Book et al.
[16]). All patients will also be asked to record their pain
history by using a pain diary (documentation of medica-
tion daily during treatment and once weekly after the
completion of treatment, VAS pain scale). The pain
response is documented on the VAS (range of 0–10).
Complete response is defined as VAS score of 0/10 after
three or six months and partial response is defined as a
reduced value by at least 2 points after three or six
months, according to the international consensus
response categories by Chow et al. [17]. Overall survival
is defined as time from initial diagnosis until death and
bone survival is defined as time from initial diagnosis of
irradiated spinal bone metastasis until death (Additional
file 1).
Radiotherapy
Treatment will be planned three-dimensionally using CT
scan with a 3-mm slice thickness taken across the involved
vertebral region. Immobilization is ensured with an Aqua-
plast head mask (Aquaplast Corporation, Wyckoff, NJ,
USA), vacuum mattress, and Wingstep® (Elekta, Stockholm,
Sweden). On the basis of the planning CT, organs at risk will
be contoured. The spinal cord is contoured on the basis of
Fig. 2 Timeline IRON-2: RT radiotherapy, IMRT
intensity-modulated radiotherapy
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visible target on the CT scan with the help of fusion with the
MRI data.
The SIB includes the macroscopic tumor. Gross tumor
volume (GTV) includes the metastasis. GTV plus 3-mm
safety margin gives CTV. CTV corresponds to planning
target volume (PTV).
The GTV includes the macroscopic metastatsis. The
CTV covers the entire vertebral body including posterior
structures (pedicles, processi, and arcus). The CTV with
an addition of 3 mm produces PTV. The PTV includes
the tumorous vertebra will be covered by the 90% isodose.
Radiation will be applied as IMRT (tomotherapy or
step-and-shoot IMRT or volumetric modulated arc ther-
apy [VMAT], energy of 6 MV) using 30 Gy in ten
fractions, or 30 Gy in ten fractions and SIB to 40 Gy in
ten fractions, or 20 Gy in five fractions, or 20 Gy in five
fractions and SIB to 30 Gy. Tolerance doses of the or-
gans at risk are based on the data published for the
RTOG 06-31 study [18].
Therapy drop-out criteria
 Patient’s wish
 Medical condition requiring the discontinuation of
therapy in the opinion of the study director or patient
 Insufficient compliance
In case of early drop-out from the study, the planned
follow-up scheme will be continued. For non-evaluable
patients, the reason will be recorded in the case report
forms. Study patients will have the opportunity to refuse
individual investigations.
Statistical analysis
Due to the explorative character of this study, it was not
possible to estimate the total number of cases; with a
scheduled number of 30 patients per group, it will, how-
ever, be possible to detect a standardized mean-value ef-
fect (Cohen’s d) of 0.74 with a power of 80% and a
significance level of 5%, if a one-factorial variance analysis
is calculated. All variables will be analyzed descriptively by
tabulation of the measures of the empirical distributions.
In case of continuous variables mean values, standard
deviations, median, minimum, and maximum values will
be documented. Categorical variables will be documented
as occurrence and percentage. The primary endpoint will
be measured by CT. Results will be presented at three
months after completion of RT and differences between
groups will be calculated using a one-factorial variance
analysis. Differences of categorical variables will be calcu-
lated with the Chi-square test. The survival analysis will
be performed using the Kaplan–Meier method and log-
rank test.
All statistical analyses will be carried out descriptively
using SAS software Version 9.4 or higher (SAS Institute,
Cary, NC, USA).
Ethical issues, information, and safety
The study protocol, patient information sheet, and in-
formed consent forms were submitted to the Independ-
ent Ethics Committee of Heidelberg University.
Approval was given in 2016 (#S-483/2016). Additional
recommendations were provided by the committee of
experts of the radio-oncology organization in Germany.
The study directors will immediately notify the Ethics
Committee of all changes made in the study protocol
that may have an impact on the safety of the patients.
Furthermore, the Ethics Committee will also be notified
of all severe adverse events reported to the study
directors and of the regular or premature termination of
the study. The procedures described in the submitted
study protocol regarding the performance, evaluation,
and documentation of this study has been selected in
such a way that the principles of the Good Clinical Prac-
tice guidelines are observed. The regulations regarding
medical confidentiality and data protection are fulfilled.
Discussion
Palliative therapy aims to relieve suffering during all stages
of disease and does not have to be limited to end-of-life
care. Despite advances in palliative therapies, cancer is still
a great burden for patients and painful vertebral bone
metastases can strongly reduce the patients’ wellbeing.
Limitations of QoL, such as posture changes, reduced
movement and pain, fractures, and immobility, can be
consequences of vertebral metastases. Therefore, im-
proved QoL in this palliative situation is of pivotal import-
ance. RT has been established as an effective local
treatment for vertebral metastases. Therapy goals are a
reduction in pain and fatigue, improvement of QoL, pre-
vention of pathological fractures, or neurological deficits.
For patients with vertebral metastases, dose escalations
may result in improved tumor control. Since the stan-
dardized irradiation volume comprises the spinal cord, it
is not possible to reduce radiation doses to the spinal
cord even with modern technologies such as IMRT.
Adding a SIB to the treatment may result in significant
dose reductions in the spinal cord compared to conven-
tional IMRT. Recent trials tested 30 Gy in ten fractions
and 40 Gy in five fractions to bone metastases respect-
ively, but these doses are most likely insufficient regard-
ing local tumor control. Therefore, our hypothesis holds
that a SIB to the bone metastasis might overcome this
problem. A previously published planning study by Lee
et al. has shown that IMRT can deliver the concomitant
hypofractionated regime proposed and offer benefits in
dose delivery. IMRT and VMAT are currently preferred
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for their superior pre-treatment verification results and
shorter planning times [19]. Potential influence on the
local control rate of the different IMRT techniques will
be investigated in this study. Specifically, the differences
in conformity and homogeneity of helical IMRT vs step-
and- shoot or VMAT-IMRT techniques are examined in
a subgroup analysis.
SBRT has been shown in prospective trials and numer-
ous case series to be safe and effective for the treatment
of spinal bone lesions as well as primary bone tumors.
One comparison of the palliative efficacy and cost-
effectiveness of external beam RT compared with SBRT
as a primary treatment for spinal metastases found that
patients treated with external beam RT had increased
acute toxicities and there was a higher likelihood of
them requiring further intervention at the treated sites.
A recent trial showed that SIB-IMRT could be success-
fully applied to vertebral metastases with spinal cord
compression in up to four consecutive vertebrae. Good
ADL preservation and pain control were achieved with
acceptable toxicity [20]. Lubgan et al. demonstrate excel-
lent local control rate of 93% after 24 months in 33
patients who underwent SBRT with SIB. No radiation
myelopathy occurred [21]. Nevertheless, the optimal
dose schedule could not be found and no prospective
trial has been investigated in this setting so far.
Trial status
Patient recruitment not completed.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. The additional SPIRIT
2013 Checklist file shows this in more detail. (DOC 121 kb)
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